Phio Pharmaceuticals Corp. (PHIO) Stock Analysis & Investment Frameworks
Phio Pharmaceuticals Corp. (PHIO) stock analysis on Invetso. Review Phio Pharmaceuticals Corp.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Phio Pharmaceuticals Corp. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Phio Pharmaceuticals Corp. Key Financial Metrics
- Market Cap: $10.49M
- Revenue: $N/A
- ROE: -87.41%
- ROIC: -100.51%
- Dividend Yield: N/A
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Phio Pharmaceuticals Corp. Investment Frameworks
Invetso analyzes Phio Pharmaceuticals Corp. (PHIO) across the following frameworks:
- Phio Pharmaceuticals Corp. 10Y Growth Potential
- Phio Pharmaceuticals Corp. Scenario Analysis
- Phio Pharmaceuticals Corp. Risks & Opportunities
- Phio Pharmaceuticals Corp. Economic Moat
- Phio Pharmaceuticals Corp. Business Model
- Phio Pharmaceuticals Corp. Management
- Phio Pharmaceuticals Corp. SWOT Analysis
- Phio Pharmaceuticals Corp. Porter's 5 Forces
- Phio Pharmaceuticals Corp. PESTLE Analysis
- Phio Pharmaceuticals Corp. ESG Analysis